Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| United States Department of Defense | FED |
Not provided
Not provided
Not provided
Not provided
Children with neurofibromatosis type 1 (NF1) commonly suffer from the effects of cognitive, behavioral, and motor impairments. At present, there is no specific treatment for this NF1 complication. In this project, the investigators will assess the safety and clinical benefit of N-acetylcysteine (NAC) as a pharmacological intervention in children with NF1. This drug choice is based on the recent findings from mouse models to study the central nervous system manifestations of NF1 at Cincinnati Children's Hospital Medical Center (CCHMC). These findings revealed a role for myelin-forming oligodendrocytes in the control of nitric oxide synthases (NOS) and their product, nitric oxide (NO), in maintenance of brain structure and function, including regulation of behavior and motor control. Treating these mice with NAC corrected cellular and behavioral abnormalities. This data from animal models of NF1 along with uncontrolled clinical observations in children with NF1 suggest that the antioxidant compound, NAC, may reduce these impairments. Therefore, the investigators propose performing a single center double-blind placebo controlled, prospective, Phase II study to explore safety, tolerability, and efficacy of NAC on motor behavior and/or learning in children with NF1 aged 8 through 16 years old. Participants will be carefully monitored for side effects. Primary and secondary outcome measures will be administered at baseline, follow-up, and post-treatment.
This is a phase II clinical trial with the goal to explore safety, tolerability, and efficacy of NAC on motor behavior in children with NF1 aged 8 through 16 years old. The investigators hypothesize that NAC therapy will improve motor function evaluated by the Physical and Neurological Examination for Soft Signs (PANESS) scale. This is based on studies demonstrating that NAC significantly improved impairments in the animal model of NF1. The investigators will also analyze NAC effects on attention deficit and impulsivity in children with NF1.
This study will also help develop novel predictive biomarkers of response to neurocognitive therapies in patients with NF1 which are needed to evaluate treatment outcomes.
The investigators will gain information in children with NF1 about possible clinical benefit of anti-oxidant treatment and to develop and evaluate quantitative brain-based and blood biomarkers relating to presence of NF1, symptom severity, and response to antioxidant therapy. Clinically, 50 percent of children with NF1 are underperforming or failing at school. This frequently leads to decreased educational attainment and fewer opportunities as adults. An important first step was preliminary work using the PANESS scale and Transcranial Magnetic Stimulation (TMS)-evoked Short Interval Cortical Inhibition (SICI) in children with NF1. The investigators propose to develop and extend understanding of NF1-related motor and learning behavior in response to antioxidant therapy with NAC. The purpose of the present study is to 1) evaluate tolerability, safety, and clinical benefit of NAC in this double-blind placebo controlled study using the motor function scale (PANESS); 2) to evaluate the effects of NAC on measures of NF1 neurocognitive symptomatology (ADHD/impulsive symptoms, executive function, working memory); and 3) to determine if TMS measurement (SICI) in children with NF1 will correlate with clinical effects of NAC treatment and evaluate utility of advanced brain imaging and spectroscopy measurements in children with NF1, and effects of NAC therapy.
The investigators propose to study 58 children with NF1, ages 8-16 years, at baseline and after completion of 8 weeks of treatment with NAC, followed by a washout period of 4 weeks.
The investigators believe this work has the potential to lay groundwork for future use of relevant biomarkers for treatment and outcomes research for NF1 as well as other biologically similar conditions, collectively designated the "RASopathies" (due to involvement of a protein first discovered in rat sarcomas (RAS), but not technically an acronym). RAS is family of proteins. This work may ultimately guide development of more effective treatments based on disease pathophysiology.
STUDY OBJECTIVE:
NAC Trial at Cincinnati Children's Hospital Medical Center (CCHMC) The investigators propose performing a single center randomized double-blind placebo controlled, prospective, Phase II study to explore safety, tolerability, and efficacy of NAC on motor behavior in children with NF1 aged 8 through 16 years old.
Hypothesis:
The investigators hypothesize that NAC therapy will improve motor function evaluated by the PANESS scale. This is based on studies demonstrating that NAC significantly improved impairments in the animal model of NF1. The investigators will also analyze NAC effects on attention deficit and impulsivity in children with NF1.
Specific Aim:
The primary outcome of this study is to characterize the effects of NAC treatment on motor function in children and adolescents with NF1 using the PANESS. The investigators hypothesize that motor function scores rated with the PANESS scale will improve after treatment with NAC.
Secondary Aims:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| N-Acetylcysteine (NAC) | Experimental | Each subject will be dosed with approximately 70 mg/kg/day of NAC for 8 weeks. To facilitate drug compounding, three tiers of drug dose will be administered based on body weight as described in Table 3. Table 3: NAC Dosing Participant's weight (kg) Dose (BID) < 20 700 mg 21-39 1050 mg > 40 1350 mg *Max dose not to exceed 2700mg/day (1350mg BID) |
|
| Placebo | Placebo Comparator | Each subject will be dosed with placebo for 8 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| N-Acetyl cysteine | Drug | Eight (8) weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Motor Function Measured by Physical and Neurological Examination for Soft Signs (PANESS) | Characterize effects of NAC treatment on motor function in kids with NF1 using the Physical and Neurological Examination for Soft Signs (PANESS). This is a validated scale that consistently demonstrates significant impairments in children with ADHD, and which preliminary data suggest may demonstrate more extreme problems in children with NF1 than age-matched healthy controls (unpublished data from CCHMC). The investigators hypothesize that motor function scores rated with the PANESS scale will improve after treatment with NAC. The range of this scale is 0-119, higher scores correlate with symptom severity (worse outcome). | Baseline vs. end of treatment, 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in ADHD Symptoms as Reported Via Parent/Teacher Surveys | Characterize effects of NAC treatment on ADHD symptoms in children with NF1. The investigators hypothesize that ADHD attention and hyperactive/impulsive symptoms, rated with the Diagnostic and Statistical Manual (DSM-5) based clinical rating scales, will improve after treatment with NAC. The range of this scale is 0-56, higher scores correlate with symptom severity (worse outcome). |
Not provided
Inclusion Criteria ѱ:
You can be in this study if you have any of the following:
Exclusion Criteria:
You cannot be in this study if you have any of the following:
ѱ Indicates Inclusion/Exclusion Criteria for the treatment- and non-treatment cohorts (no mark indicates exclusion requirements for the 12-week treatment-cohort only).
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Donald Gilbert, MD MS | Children's Hospital Medical Center, Cincinnati | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 16522267 | Background | Acosta MT, Gioia GA, Silva AJ. Neurofibromatosis type 1: new insights into neurocognitive issues. Curr Neurol Neurosci Rep. 2006 Mar;6(2):136-43. doi: 10.1007/s11910-996-0036-5. | |
| 2121371 | Background | Ballester R, Marchuk D, Boguski M, Saulino A, Letcher R, Wigler M, Collins F. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell. 1990 Nov 16;63(4):851-9. doi: 10.1016/0092-8674(90)90151-4. |
Not provided
Not provided
Data tables, with de-identified individual participant data, will be stored at Mendeley Data
Beginning 3 months after publication with no end date
Access is through the Mendeley website. No proposal or data sharing agreement needed.
After screening and baseline assessments, participants were randomized 1:1 to receive N-acetylcysteine (NAC) or matching placebo using permuted block randomization stratified by age, sex, and ADHD status. The study was double-blind; only the investigational pharmacy was unblinded. NAC was administered orally for 8 weeks at ~70 mg/kg/day divided BID with weight-based dosing. Placebo was identical in appearance and schedule.
Recruitment occurred through clinic and IRB-approved study registry review. Determination of enrollment eligibility was a multi-step process. The study team screened and reviewed medical histories of 481 children and adolescents with NF1, of whom 203 (42%) were deemed eligible. From this eligible group, 25 (12%) agreed to participate. The first patient was enrolled and randomized February 23, 2021 and the last completed a final treatment visit November 13, 2023.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | N-Acetylcysteine (NAC) | Each subject will be dosed with approximately 70 mg/kg/day of NAC for 8 weeks. To facilitate drug compounding, three tiers of drug dose will be administered based on body weight as described in Table 3. Table 3: NAC Dosing Participant's weight (kg) Dose (BID) < 20 700 mg 21-39 1050 mg > 40 1350 mg *Max dose not to exceed 2700mg/day (1350mg BID) N-Acetyl cysteine: Eight (8) weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC). |
| FG001 | Placebo | Each subject will be dosed with placebo for 8 weeks. Placebo: Eight (8) weeks of treatment with placebo. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Study participation at baseline was exactly the same for participants in both arms.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | N-Acetylcysteine (NAC) | Each subject will be dosed with approximately 70 mg/kg/day of NAC for 8 weeks. To facilitate drug compounding, three tiers of drug dose will be administered based on body weight as described in Table 3. Table 3: NAC Dosing Participant's weight (kg) Dose (BID) < 20 700 mg 21-39 1050 mg > 40 1350 mg *Max dose not to exceed 2700mg/day (1350mg BID) N-Acetyl cysteine: Eight (8) weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC). |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in Motor Function Measured by Physical and Neurological Examination for Soft Signs (PANESS) | Characterize effects of NAC treatment on motor function in kids with NF1 using the Physical and Neurological Examination for Soft Signs (PANESS). This is a validated scale that consistently demonstrates significant impairments in children with ADHD, and which preliminary data suggest may demonstrate more extreme problems in children with NF1 than age-matched healthy controls (unpublished data from CCHMC). The investigators hypothesize that motor function scores rated with the PANESS scale will improve after treatment with NAC. The range of this scale is 0-119, higher scores correlate with symptom severity (worse outcome). | 25 were enrolled and randomized (12 active NAC; 13 placebo). 2 (NAC group) were withdrawn after randomization, before receiving drug and were not analyzed. 2 (NAC group) withdrew during treatment, prior to primary outcome assessment at week 8. Therefore, completer analysis was done with 8 NAC, 13 placebo, at week 8. We also did intention to treat with 10 NAC, 13 placebo, using last observation carried forward. For the 12-week washout analysis, one NAC was lost to follow up. | Posted | Mean | Standard Deviation | units on a scale | Baseline vs. end of treatment, 8 weeks |
12 weeks
Participants and/or their parents received scheduled assessments as outlined in the study protocol. These included prompts such as 'Have there been any changes in your health since the last visit?' and 'Is there anything you would like to share with the study team?' Responses were reviewed and monitored by study personnel.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | N-Acetylcysteine (NAC) | Each subject will be dosed with approximately 70 mg/kg/day of NAC for 8 weeks. To facilitate drug compounding, three tiers of drug dose will be administered based on body weight as described in Table 3. Table 3: NAC Dosing Participant's weight (kg) Dose (BID) < 20 700 mg 21-39 1050 mg > 40 1350 mg *Max dose not to exceed 2700mg/day (1350mg BID) N-Acetyl cysteine: Eight (8) weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC). |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Constipation | Gastrointestinal disorders | MedDRA (Unspecified) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Donald L. Gilbert MD | Cincinnati Children's Hospital Medical Center | 513-636-4222 | donald.gilbert@cchmc.org |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | May 17, 2023 | Jul 7, 2023 | Prot_SAP_002.pdf |
| ICF | No | No | Yes | Informed Consent Form | May 17, 2023 | Jul 7, 2023 | ICF_003.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009456 | Neurofibromatosis 1 |
| D001289 | Attention Deficit Disorder with Hyperactivity |
| ID | Term |
|---|---|
| D017253 | Neurofibromatoses |
| D009455 | Neurofibroma |
| D018317 | Nerve Sheath Neoplasms |
| D009380 | Neoplasms, Nerve Tissue |
Not provided
Not provided
| ID | Term |
|---|---|
| D000111 | Acetylcysteine |
| D001239 | Inhalation |
| C030905 | N-monoacetylcystine |
| ID | Term |
|---|---|
| D003545 | Cysteine |
| D000603 | Amino Acids, Sulfur |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
Not provided
Not provided
This is a phase II, double blind, placebo-controlled clinical trial with the goal to explore safety, tolerability, and efficacy of N-acetylcysteine (NAC).
Not provided
Not provided
In order to preserve the double-masking of the trial, only the investigation pharmacy will be unmasked. Both treatments (NAC and placebo) will be distributed from the investigational pharmacy. Except for the pharmacist, all staff will be blinded to the treatment sequence.
| Placebo | Other | Eight (8) weeks of treatment with placebo. |
|
| baseline vs. end of treatment, 8 weeks |
| Change From Baseline in Motor Cortex Inhibition/Excitation Measures, Expressed as Ratios of Single to Paired Pulse Transcranial Magnetic Stimulation (TMS) Motor Evoked Potential Amplitudes | Describe the function and physiology of the motor system using Transcranial Magnetic Stimulation (TMS) as a possible disease biomarker of NF1. Output is quantified from surface EMG tracings after motor cortex stimulation with TMS. SICI, ICF, and LICI are standard paired pulse (condition/test-pulse) measures where the outcome is expressed as a ratio of motor evoked potential amplitudes. Ratios < 1.0 represent inhibition, ratios > 1.0 represent facilitation. CSP is a silent period in EMG activity, measure in milliseconds (ms). | baseline vs. end of treatment, 8 weeks |
| Change From Baseline in Motor Cortex Inhibition/Excitation Measures, Expressed as Milliseconds of Single to Paired Pulse Transcranial Magnetic Stimulation (TMS) Motor Evoked Potential Amplitudes | Describe the function and physiology of the motor system using Transcranial Magnetic Stimulation (TMS) as a possible disease biomarker of NF1. Output is quantified from surface EMG tracings after motor cortex stimulation with TMS. CSP is a silent period in EMG activity, measure in milliseconds (ms). | baseline vs. end of treatment, 8 weeks |
| Change From Baseline in Microstructural Properties of Brain Tissue Visualized by Magnetic Resonance Imaging (MRI) | To quantify microstructural properties of brain tissue based on water diffusion, glutathione (GSH) concentration, glutamate/glutamine (GLX) concentration, and gamma-aminobutyric acid (GABA) concentration using brain magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) in children with NF1. This will allow for regional correlation between imaging, spectroscopy and neuropsychometric outcomes. We will also determine if these magnetic resonance based outcomes correlate with clinical effects of NAC treatment. | baseline vs. end of treatment, 8 weeks |
| 12583841 | Background | Rosser TL, Packer RJ. Neurocognitive dysfunction in children with neurofibromatosis type 1. Curr Neurol Neurosci Rep. 2003 Mar;3(2):129-36. doi: 10.1007/s11910-003-0064-3. |
| 25284746 | Background | Casnar CL, Janke KM, van der Fluit F, Brei NG, Klein-Tasman BP. Relations between fine motor skill and parental report of attention in young children with neurofibromatosis type 1. J Clin Exp Neuropsychol. 2014;36(9):930-43. doi: 10.1080/13803395.2014.957166. Epub 2014 Oct 6. |
| 27527646 | Background | Walsh KS, Janusz J, Wolters PL, Martin S, Klein-Tasman BP, Toledo-Tamula MA, Thompson HL, Payne JM, Hardy KK, de Blank P, Semerjian C, Gray LS, Solomon SE, Ullrich N; REiNS International Collaboration. Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention. Neurology. 2016 Aug 16;87(7 Suppl 1):S21-30. doi: 10.1212/WNL.0000000000002928. |
| 22821737 | Background | Acosta MT, Bearden CE, Castellanos FX, Cutting L, Elgersma Y, Gioia G, Gutmann DH, Lee YS, Legius E, Muenke M, North K, Parada LF, Ratner N, Hunter-Schaedle K, Silva AJ. The Learning Disabilities Network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research. Am J Med Genet A. 2012 Sep;158A(9):2225-32. doi: 10.1002/ajmg.a.35535. Epub 2012 Jul 20. |
| 20142468 | Background | Pride N, Payne JM, Webster R, Shores EA, Rae C, North KN. Corpus callosum morphology and its relationship to cognitive function in neurofibromatosis type 1. J Child Neurol. 2010 Jul;25(7):834-41. doi: 10.1177/0883073809350723. Epub 2010 Feb 8. |
| 22901811 | Background | Wang Y, Kim E, Wang X, Novitch BG, Yoshikawa K, Chang LS, Zhu Y. ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities. Cell. 2012 Aug 17;150(4):816-30. doi: 10.1016/j.cell.2012.06.034. |
| 23094098 | Background | Karlsgodt KH, Rosser T, Lutkenhoff ES, Cannon TD, Silva A, Bearden CE. Alterations in white matter microstructure in neurofibromatosis-1. PLoS One. 2012;7(10):e47854. doi: 10.1371/journal.pone.0047854. Epub 2012 Oct 19. |
| 21321335 | Background | Gilbert DL, Isaacs KM, Augusta M, Macneil LK, Mostofsky SH. Motor cortex inhibition: a marker of ADHD behavior and motor development in children. Neurology. 2011 Feb 15;76(7):615-21. doi: 10.1212/WNL.0b013e31820c2ebd. |
| 24413361 | Background | Chen TH, Wu SW, Welge JA, Dixon SG, Shahana N, Huddleston DA, Sarvis AR, Sallee FR, Gilbert DL. Reduced short interval cortical inhibition correlates with atomoxetine response in children with attention-deficit hyperactivity disorder (ADHD). J Child Neurol. 2014 Dec;29(12):1672-9. doi: 10.1177/0883073813513333. Epub 2014 Jan 10. |
| 18164210 | Background | Dennis J, White MA, Forrest AD, Yuelling LM, Nogaroli L, Afshari FS, Fox MA, Fuss B. Phosphodiesterase-Ialpha/autotaxin's MORFO domain regulates oligodendroglial process network formation and focal adhesion organization. Mol Cell Neurosci. 2008 Feb;37(2):412-24. doi: 10.1016/j.mcn.2007.10.018. Epub 2007 Nov 12. |
| 12176993 | Background | Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K, Fukuzawa K. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem. 2002 Oct 18;277(42):39436-42. doi: 10.1074/jbc.M205623200. Epub 2002 Aug 9. |
| 12837632 | Background | Fox MA, Colello RJ, Macklin WB, Fuss B. Phosphodiesterase-Ialpha/autotaxin: a counteradhesive protein expressed by oligodendrocytes during onset of myelination. Mol Cell Neurosci. 2003 Jul;23(3):507-19. doi: 10.1016/s1044-7431(03)00073-3. |
| 24987341 | Background | Chen YW, Lin HC, Ng MC, Hsiao YH, Wang CC, Gean PW, Chen PS. Activation of mGluR2/3 underlies the effects of N-acetylcystein on amygdala-associated autism-like phenotypes in a valproate-induced rat model of autism. Front Behav Neurosci. 2014 Jun 17;8:219. doi: 10.3389/fnbeh.2014.00219. eCollection 2014. |
| 24035394 | Background | Mayes DA, Rizvi TA, Titus-Mitchell H, Oberst R, Ciraolo GM, Vorhees CV, Robinson AP, Miller SD, Cancelas JA, Stemmer-Rachamimov AO, Ratner N. Nf1 loss and Ras hyperactivation in oligodendrocytes induce NOS-driven defects in myelin and vasculature. Cell Rep. 2013 Sep 26;4(6):1197-212. doi: 10.1016/j.celrep.2013.08.011. Epub 2013 Sep 12. |
| 23400548 | Background | Garcia RJ, Francis L, Dawood M, Lai ZW, Faraone SV, Perl A. Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus. Arthritis Rheum. 2013 May;65(5):1313-8. doi: 10.1002/art.37893. |
| 27137430 | Background | Fernandes BS, Dean OM, Dodd S, Malhi GS, Berk M. N-Acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis. J Clin Psychiatry. 2016 Apr;77(4):e457-66. doi: 10.4088/JCP.15r09984. |
| 22342106 | Background | Hardan AY, Fung LK, Libove RA, Obukhanych TV, Nair S, Herzenberg LA, Frazier TW, Tirouvanziam R. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry. 2012 Jun 1;71(11):956-61. doi: 10.1016/j.biopsych.2012.01.014. Epub 2012 Feb 18. |
| 21719110 | Background | Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS, Kohlmann K, Jeavons S, Hewitt K, Allwang C, Cobb H, Bush AI, Schapkaitz I, Dodd S, Malhi GS. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord. 2011 Dec;135(1-3):389-94. doi: 10.1016/j.jad.2011.06.005. Epub 2011 Jun 29. |
| 11323729 | Background | Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med. 2001 Apr 26;344(17):1279-85. doi: 10.1056/NEJM200104263441703. |
| 11911230 | Background | Axelrod BN. Validity of the Wechsler abbreviated scale of intelligence and other very short forms of estimating intellectual functioning. Assessment. 2002 Mar;9(1):17-23. doi: 10.1177/1073191102009001003. |
| 11771629 | Background | Zhu J, Tulsky DS, Price L, Chen HY. WAIS-III reliability data for clinical groups. J Int Neuropsychol Soc. 2001 Nov;7(7):862-6. |
| 9140363 | Background | Mills KR, Nithi KA. Corticomotor threshold to magnetic stimulation: normal values and repeatability. Muscle Nerve. 1997 May;20(5):570-6. doi: 10.1002/(sici)1097-4598(199705)20:53.0.co;2-6. |
| 10590943 | Background | Ziemann U. Intracortical inhibition and facilitation in the conventional paired TMS paradigm. Electroencephalogr Clin Neurophysiol Suppl. 1999;51:127-36. No abstract available. |
| 26537928 | Background | Erkan E, Zhao X, Setchell K, Devarajan P. Distinct urinary lipid profile in children with focal segmental glomerulosclerosis. Pediatr Nephrol. 2016 Apr;31(4):581-8. doi: 10.1007/s00467-015-3239-7. Epub 2015 Nov 4. |
| 9474057 | Background | Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. Electroencephalogr Clin Neurophysiol. 1998 Jan;108(1):1-16. doi: 10.1016/s0168-5597(97)00096-8. |
| 36996759 | Result | Doherty AC, Huddleston DA, Horn PS, Ratner N, Simpson BN, Schorry EK, Aschbacher-Smith L, Prada CE, Gilbert DL. Motor Function and Physiology in Youth With Neurofibromatosis Type 1. Pediatr Neurol. 2023 Jun;143:34-43. doi: 10.1016/j.pediatrneurol.2023.02.014. Epub 2023 Mar 3. |
| Adverse Event |
|
| BG001 | Placebo | Each subject will be dosed with placebo for 8 weeks. Placebo: Eight (8) weeks of treatment with placebo. |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
| ID | Title | Description |
|---|---|---|
| OG000 | N-Acetylcysteine (NAC) | Each subject will be dosed with approximately 70 mg/kg/day of NAC for 8 weeks. To facilitate drug compounding, three tiers of drug dose will be administered based on body weight as described in Table 3. Table 3: NAC Dosing Participant's weight (kg) Dose (BID) < 20 700 mg 21-39 1050 mg > 40 1350 mg *Max dose not to exceed 2700mg/day (1350mg BID) N-Acetyl cysteine: Eight (8) weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC). |
| OG001 | Placebo | Each subject will be dosed with placebo for 8 weeks. Placebo: Eight (8) weeks of treatment with placebo. |
|
|
|
| Secondary | Change From Baseline in ADHD Symptoms as Reported Via Parent/Teacher Surveys | Characterize effects of NAC treatment on ADHD symptoms in children with NF1. The investigators hypothesize that ADHD attention and hyperactive/impulsive symptoms, rated with the Diagnostic and Statistical Manual (DSM-5) based clinical rating scales, will improve after treatment with NAC. The range of this scale is 0-56, higher scores correlate with symptom severity (worse outcome). | Posted | Mean | Standard Deviation | score on a scale | baseline vs. end of treatment, 8 weeks |
|
|
|
|
| Secondary | Change From Baseline in Motor Cortex Inhibition/Excitation Measures, Expressed as Ratios of Single to Paired Pulse Transcranial Magnetic Stimulation (TMS) Motor Evoked Potential Amplitudes | Describe the function and physiology of the motor system using Transcranial Magnetic Stimulation (TMS) as a possible disease biomarker of NF1. Output is quantified from surface EMG tracings after motor cortex stimulation with TMS. SICI, ICF, and LICI are standard paired pulse (condition/test-pulse) measures where the outcome is expressed as a ratio of motor evoked potential amplitudes. Ratios < 1.0 represent inhibition, ratios > 1.0 represent facilitation. CSP is a silent period in EMG activity, measure in milliseconds (ms). | TMS data not available on all participants - one participant refused; several had high resting motor thresholds precluding obtaining data for some measures | Posted | Mean | Standard Deviation | ratios of paired to single pulse MEPs | baseline vs. end of treatment, 8 weeks |
|
|
|
|
| Secondary | Change From Baseline in Motor Cortex Inhibition/Excitation Measures, Expressed as Milliseconds of Single to Paired Pulse Transcranial Magnetic Stimulation (TMS) Motor Evoked Potential Amplitudes | Describe the function and physiology of the motor system using Transcranial Magnetic Stimulation (TMS) as a possible disease biomarker of NF1. Output is quantified from surface EMG tracings after motor cortex stimulation with TMS. CSP is a silent period in EMG activity, measure in milliseconds (ms). | TMS data not available on all participants - one participant refused; several had high resting motor thresholds precluding obtaining data for some measures | Posted | Mean | Standard Deviation | milliseconds (ms) | baseline vs. end of treatment, 8 weeks |
|
|
|
|
| Secondary | Change From Baseline in Microstructural Properties of Brain Tissue Visualized by Magnetic Resonance Imaging (MRI) | To quantify microstructural properties of brain tissue based on water diffusion, glutathione (GSH) concentration, glutamate/glutamine (GLX) concentration, and gamma-aminobutyric acid (GABA) concentration using brain magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) in children with NF1. This will allow for regional correlation between imaging, spectroscopy and neuropsychometric outcomes. We will also determine if these magnetic resonance based outcomes correlate with clinical effects of NAC treatment. | Data quality review led to removal of participant data for some outcomes. Adequate MR Spectroscopy data for NAC group ranged from 5 to 8 participants, for Placebo group from 9 to 11 participants. | Posted | Mean | Standard Deviation | mM | baseline vs. end of treatment, 8 weeks |
|
|
|
|
| 0 |
| 12 |
| 0 |
| 12 |
| 4 |
| 12 |
| EG001 | Placebo | Each subject will be dosed with placebo for 8 weeks. Placebo: Eight (8) weeks of treatment with placebo. | 0 | 13 | 0 | 13 | 5 | 13 |
| Abdominal pain | Gastrointestinal disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Infection | Infections and infestations | MedDRA (Unspecified) | Systematic Assessment | 1 streptococcal pharyngitis (placebo), 2 fevers (both placebo), 1 Viral conjunctivitis (placebo), 1 cold (placebo) |
|
| Irritability | Psychiatric disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Anxiety | Psychiatric disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Fatigue | General disorders | MedDRA (Unspecified) | Systematic Assessment |
|
Not provided
Not provided
| D009370 |
| Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009386 | Neoplastic Syndromes, Hereditary |
| D020752 | Neurocutaneous Syndromes |
| D009422 | Nervous System Diseases |
| D020271 | Heredodegenerative Disorders, Nervous System |
| D019636 | Neurodegenerative Diseases |
| D010523 | Peripheral Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D019958 | Attention Deficit and Disruptive Behavior Disorders |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |
| D000596 |
| Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
| D015656 | Respiratory Mechanics |
| D012119 | Respiration |
| D012143 | Respiratory Physiological Phenomena |
| D002943 | Circulatory and Respiratory Physiological Phenomena |
| Intracortical Facilitation (ICF) |
|
|
| Long interval cortical inhibition (LICI) |
|
|
| 0.5 |
ICF |
| Superiority |
| Wilcoxon (Mann-Whitney) | 0.02 | LICI | Superiority |
| GLX |
|
|
| GLU |
|
|
| GSH |
|
|
| Cr |
|
|
| Cho |
|
|
| NAA |
|
|
GLX
| Superiority |
| t-test, 2 sided | 0.24 | GSH | Superiority |
| Wilcoxon (Mann-Whitney) | 0.50 | Uncorrected; GABA | Superiority |
| Wilcoxon (Mann-Whitney) | 0.9 | GLX | Superiority |
| Wilcoxon (Mann-Whitney) | >0.9 | GLU | Superiority |
| Wilcoxon (Mann-Whitney) | 0.03 | GSH | Superiority |
| Wilcoxon (Mann-Whitney) | 0.4 | Cr | Superiority |
| Wilcoxon (Mann-Whitney) | 0.8 | Cho | Superiority |
| Wilcoxon (Mann-Whitney) | 0.5 | NAA | Superiority |